Show simple item record

dc.contributor.authorStiles, CEen_US
dc.contributor.authorThuraisingham, Ren_US
dc.contributor.authorBockenhauer, Den_US
dc.contributor.authorPlatts, Len_US
dc.contributor.authorKumar, AVen_US
dc.contributor.authorKorbonits, Men_US
dc.date.accessioned2018-04-09T13:32:59Z
dc.date.available2018-02-27en_US
dc.date.issued2018en_US
dc.date.submitted2018-04-05T00:29:23.009Z
dc.identifier.issn2052-0573en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/36267
dc.description.abstract29-year-old female presenting with an 8-year history of unexplained hypomagnesaemia, which was severe enough to warrant intermittent inpatient admission for intravenous magnesium. Urinary magnesium was inappropriately normal in the context of hypomagnesaemia indicating magnesium wasting. Ultrasound imaging demonstrated unilateral renal cysts and computed tomography of kidneys, ureters and bladder showed a bicornuate uterus. Referral to genetic services and subsequent testing revealed a de novo HNF1B deletion. Learning points: HNF1B loss-of-function mutations are one of the most common monogenic causes of congenital anomalies of the kidney and urinary tract.Those with HNF1B mutations may have some of a constellation of features (renal and hepatic cysts, deranged liver function tests, maturity onset diabetes of the young type 5 (MODY5), bicornuate uterus, hyperparathyroidism, hyperuricaemic gout, but presenting features are highly heterogeneous amongst patients and no genotype/phenotype correlation exists. HNF1B mutations are inherited in an autosomal dominant pattern but up to 50% of cases are de novo.HNF1B mutations can be part of the Chr17q12 deletion syndrome, a contiguous gene deletion syndrome.Inorganic oral magnesium replacements are generally poorly tolerated with side effects of diarrhoea. Organic magnesium compounds, such as magnesium aspartate, are better absorbed oral replacement therapies.en_US
dc.description.sponsorshipThis work was supported by a Wellcome Trust Clinical Training fellowship to CES (grant number 097970/Z/11/Z).en_US
dc.languageengen_US
dc.relation.ispartofEndocrinol Diabetes Metab Case Repen_US
dc.rightsThis is an Open Access article distributed and licenced under a Creative Commons Attribution 4.0 International License.
dc.titleDe novo HNF1 homeobox B mutation as a cause for chronic, treatment-resistant hypomagnesaemia.en_US
dc.typeArticle
dc.rights.holder© 2018 The authors.
dc.identifier.doi10.1530/EDM-17-0120en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29576871en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume2018en_US
dcterms.dateAccepted2018-02-27en_US
qmul.funderAnalysis of the involvement of AIP in tumourigenic signalling pathways in pituitary tumours and its role as a circulating peptide::Wellcome Trusten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record